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Background: The safety and efficacy of Ciprodex® has been demonstrated for treatment of chronic suppurative otitis
media (CSOM). However, symptoms fail to resolve in 9-15% of patients. The objective of this study is to evaluate the
efficacy of N-acetylcysteine (NAC) on S. aureus, and planktonic and sessile (biofilm forming) P. aeruginosa in vitro using
clinical isolates from patients with CSOM.
Methods: 1) Stability was assessed using liquid chromatography-mass spectrometry for each component in a prepared
mixture of Ciprodex® and NAC over 15 days. Sterility was assessed by measuring bacterial growth on a blood agar
plate. Efficacy was assessed using a disc diffusion method by inoculating plates with S. aureus ATCC 29513 and
P. aeruginosa ATCC 27853, and measuring the clearance zone.
2) Fifteen P. aeruginosa strains were isolated from patients with CSOM and tested in vitro using the bioFILM PA™
antimicrobial susceptibility assay. Treatment solutions included Ciprodex® & ciprofloxacin +/- NAC, and NAC alone
(0.25%, 0.5% & 1.25%).
Results: 1) NAC combined with Ciprodex® demonstrated stability, sterility, and efficacy over a two-week period
2) P. aeruginosa strains in the sessile (33%-40%) and planktonic (13%) state demonstrated resistance to Ciprodex® and
ciprofloxacin. When NAC ≥0.5% was used in isolation or as an adjunct to either of these medications, no resistance was
found in the sessile or planktonic state among all 15 strains.
Conclusion: 1) Ciprodex® combined with NAC has a shelf life of at least two weeks given the documented
preservation of stability, sterility, and clinical efficacy of the mixed compounds.
2) P. aeruginosa strains demonstrated resistance to both Ciprodex® and ciprofloxacin. NAC ≥0.5% overcomes issues
with resistance and shows promise in the treatment of CSOM.
Keywords: Otitis media, suppurative, Antibacterial agents, Microbial sensitivity tests, N-acetylcysteine, Ciprodex®,
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Chronic suppurative otitis media (CSOM) is character-
ized by chronic inflammation of the middle ear or mas-
toid, a non-intact tympanic membrane, and otorrhea
variably defined as lasting longer than two weeks to lon-
ger than three months [1-3]. The most common bacter-
ial isolates in CSOM are P. aeruginosa (18-67% of
isolates) and S. aureus (14-33%) [1-4].* Correspondence: bwesterberg@providencehealth.bc.ca
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unless otherwise stated.First line pharmacologic treatment for patients with
CSOM usually entails a combination antibiotic anti-
inflammatory (corticosteroid) topical otic drop. The
safety and efficacy of Ciprodex® (ciprofloxacin 0.3%/
dexamethasone 0.1%; Bayer AG, licensed to Alcon La-
boratories, Inc., Fort Worth, TX) has been demonstrated
in both children and adults with CSOM [5]. However,
symptoms fail to resolve in 9-15% of patients [5]. The
treatment of refractory otorrhea remains a clinical chal-
lenge for otolaryngologists.
P. aeruginosa resistance to quinolones has been docu-
mented to be as high as 18% in suppurative otitis [6]
and this coupled with recent evidence of P. aeruginosa. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment failures. Biofilm formation may sustain the in-
flammatory response that promotes persistent drainage
from the ear [9,10].
N-acetylcysteine (NAC) is best known as an antidote to
reduce liver toxicity following acetaminophen overdose
[11]. However, research in the field of otolaryngology with
this agent is not new. Prior studies have explored the util-
ity of intra-tympanic NAC in the prevention of Cisplatin
ototoxicity, and noise-induced hearing loss [12-15]. NAC
also exhibits important mucolytic and antibacterial prop-
erties, including inhibition of P. aeruginosa biofilm forma-
tion [16]. A recent case series of patients with refractory
otorrhea showed promising clinical results utilizing topical
2% NAC as an adjunct to Ciprodex® [17].
We deemed the combination of NAC and ciprofloxa-
cin warranted further study. The objectives of the
current study were to:
1. Delineate the in vitro stability, sterility and efficacy
of a mixture of ciprofloxacin and dexamethasone
(Ciprodex®) with added NAC over a two-week
period to ensure safety and preservation of bacterial
efficacy against P. aeruginosa and S. aureus; and
2. Assess the efficacy of NAC in combination with
Ciprodex® and ciprofloxacin, and NAC alone, on P.
aeruginosa clinical isolates from patients with
CSOM with a specific focus on biofilm susceptibility
in vitro.
Materials and methods
Institutional Clinical Ethics Board approval was obtained
(University of British Columbia-Providence Health Care
Research Ethics Board approval number H09-00953).
Stability, sterility and efficacy of ciprodex® in combination
with 1.25% NAC
Study solution
A 1.25% NAC solution (12.5 mg/mL) was created by add-
ing 50 μL of a commercially available 20% NAC solution
to 750 μL of Ciprodex® (ciprofloxacin 0.3%/dexametha-
sone 0.1%). This solution was prepared on day 0, stored in
a refrigerator at 4°C and used throughout the study to
measure stability, sterility and efficacy. A 15 day study
period was chosen as this corresponds to the upper limit
of a typical treatment course with topical antibiotic drops
for CSOM, and is the timeframe for which a standard
Ciprodex® bottle will be depleted if used as directed.
Stability
The concentrations of ciprofloxacin, dexamethasone (in
Ciprodex®) and NAC in the 1.25% NAC solution were mea-
sured on days 0, 1, 2, 7 and 15 by liquid chromatography-
mass spectrometry (LC-MS).Sterility data
One drop (10 uL) of the above solution was placed on a
blood agar plate on days 0, 7, and 14. The plates were
incubated at 35°C for 48 hours, at which time they were
assessed visually for bacterial growth.
Efficacy data
Using a disc diffusion method, 10 μL of the 1.25% NAC
and Ciprodex® mixture was inoculated onto plain discs and
tested on plates containing S. aureus ATCC 29513 or P.
aeruginosa ATCC 27853. The same 1.25% NAC Ciprodex®
mixture was used throughout this portion of the study, with
separate testing occurring on day 0, 7, and 14. The plates
were incubated for 24 hours at which time they were
assessed for efficacy by measuring and photo-documenting
the clearance zone around each disc.
Susceptibility of P. aeruginosa isolates in the planktonic
and sessile state
Inoculum preparation
Fifteen strains of P. aeruginosa isolated from clinical speci-
mens of patients with CSOM were tested. P. aeruginosa
ATCC 35032 was used as the quality control organism.
Treatment solutions
Twenty seven study solutions were prepared under ster-
ile conditions consisting of ciprofloxacin or Ciprodex®
alone (3, 1, and 0.5 μg/mL) and in combination with
NAC at 0.25% (2.5 mg/mL), 0.5% (5 mg/mL) and 1.25%
(12.5 mg/mL). NAC alone (no added ciprofloxacin or
Ciprodex®) was also prepared at concentrations of
0.25%, 0.5% and 1.25%. Each solution was tested in du-
plicate. Concentrations of ciprofloxacin were chosen
based on Clinical and Laboratory Standards Institute
(CLSI) guidelines [18].
Biofilm formation
For each tested strain, a 0.5 McFarland bacterial suspen-
sion was prepared from a fresh subculture grown on
blood agar plates (BAP); 300 μL of the suspension was
further diluted with 19.7 mL of trypticase soy broth
(TSB). The diluted suspension was used to inoculate a
96 well microtiter plate with a 95 peg inoculation lid
(bioFILM PA™ antimicrobial susceptibility device; Inno-
votech, Edmonton, AB). One column was inoculated
with sterile TSB alone for sterility control. The micro-
plates were incubated at 35 ± 1°C on a platform shaker
set at 110 rpm for 5 hours to allow biofilms to form on
all pegs at a standard concentration of bacterial cells.
bioFILM PA™ has received regulatory approval by Health
Canada and meets all current standards of the CLSI for
reproducibility and consistency. Standard protocols for
testing were followed.
Table 1 Stability data of N-acetylcysteine, ciprofloxacin
and dexamethasone (Ciprodex combined with 1.25%
N-acetylcysteine)
Day N-Acetylcysteine (%) Ciprofloxacin (%) Dexamethasone (%)
0 1.12 0.27 0.0953
1 1.25 0.259 0.0976
2 1.2 0.258 0.0976
7 1.16 0.315 0.0922
15 1.19 0.321 0.0953
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Isolates and control strain response to treatment solu-
tions was assessed by quantifying the optical density as a
gauge of bacterial growth. Optical density (OD) values
of ≥0.1 using a microreader at 620 nm were considered
as growth or resistance. As each solution was tested in
duplicate incongruent OD values were possible; these in-
congruent data were excluded from the analysis and cat-
egorized as non-reproducible duplicates.
a) Planktonic state: After removing the microplates
from the incubator, the pegged lids were carefully lifted
and transferred onto the “challenge plate” containing
the treatment solutions outlined above. Each
concentration and combination was tested in
duplicate. Immediately after transferring the pegged lid
to the challenge plate, an inoculum check was
performed from the growth-control wells to ensure an
acceptable bacterial load of colony forming units
(CFU) with a minimum goal of 5×105CFU/mL. The
plates were then incubated at 35 ± 1°C for 18-24 hours.
Bacterial density (growth) of the planktonic population
was assessed after incubation using measured optical
density with a microreader at 620 nm.
b) Biofilm (sessile) state: After removing the challenge
plates with the pegged lid from the incubator, the
pegged lids were transferred to a 96-well microplate
containing sterile water for 30 seconds to remove the
treatment solutions from the pegs. The pegged lid was
then transferred on to a 96-well microplate containing
cation-adjusted Mueller-Hinton broth (CAMHB) and
incubated at 35 ± 1°C for 18-24 hours to recover sessile
bacteria. Bacterial density was similarly assessed after
incubation using measured optical density with a
microreader at 620 nm.
Results
Stability, sterility and efficacy of ciprodex® in combination
with 1.25% NAC
Stability
Each component of the mixture of Ciprodex® and NAC
demonstrated stability over a 15 day period. NAC con-
centrations varied from 1.12-1.25%, ciprofloxacin from
0.27%-0.321%, and dexamethasone from 0.0922%-
0.0976% (Table 1).
Sterility
The solutions remained sterile with no evidence of bac-
terial growth throughout the 15-day study period.
Efficacy
Antimicrobial effect against both S. aureus ATCC
29513 and P. aeruginosa ATCC 27853 remained stable
based on a constant zone of inhibition around the diskcontaining the solution of Ciprodex and 1.25% NAC
on days 0, 7 and 14.Susceptibility of P. aeruginosa isolates in the planktonic
and sessile state
All strains grew in the control wells. One strain was slow
to grow with final OD levels four times lower versus other
strains, however growth was still substantial enough to
demonstrate resistance to treatment with Ciprodex and
ciprofloxacin (OD > 0.1), and therefore we included this
strain in the analysis. Inoculum control for the challenge
plates was between 6 × 10^4 and 1.7 × 10^6 cfu/mL (tar-
get: 5× 10^5 cfu/mL). Five percent of our data (42/840)
was excluded from analysis as OD values were non-
reproducible. The majority of the 42 non-reproducible du-
plicates occurred in 0.25% NAC group; the 0.25% NAC
solution accounted for 23 of the 42 non-reproducible du-
plicates, primarily an issue in the planktonic population.
Detailed resistance rates for each concentration of
Ciprodex® and ciprofloxacin are shown in Figure 1, with
combined results highlighted in Figure 2. Among the 15
P. aeruginosa strains, two showed growth when treated
with Ciprodex® or ciprofloxacin in the planktonic state,
corresponding to a resistance rate of 13%. Greater resist-
ance was seen when the bacteria were in the sessile (bio-
film) state; five (33%) and six (40%) strains showed
growth with Ciprodex® and ciprofloxacin, respectively
(Figure 2).
All 15 planktonic and sessile P. aeruginosa strains were
inhibited when NAC ≥0.5% was used alone (Figure 3) or as
an adjunct to either Ciprodex or ciprofloxacin. Interestingly
however, NAC 0.25% alone, or in combination with Cipro-
dex® or ciprofloxacin yielded inferior results in the sessile
population. Growth occurred in all but one P. aeruginosa
strain when NAC 0.25% was used in isolation, yielding a re-
sistance rate of 93% (Figure 3). Thirteen strains demon-
strated growth when NAC 0.25% was used in combination
with either Ciprodex® or ciprofloxacin for a resistance rate
of 87%. NAC 0.25% alone and in combination with either
Ciprodex® or ciprofloxacin effectively inhibited growth in
the planktonic population.
Figure 1 P. aeruginosa resistant strains to Ciprodex or ciprofloxacin at various concentrations.
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N-acetylcysteine holds promise as an adjunct in the
management of patients with chronic otitis media and
persistent otorrhea that is refractory to treatment with
standard topical antibiotic preparations. The addition of
NAC to Ciprodex® maintained a combination that was
stable, sterile and efficacious in vitro against P. aerugi-
nosa and S. aureus, up to two weeks after mixing. Fur-
thermore, in vitro testing indicated improved efficacy
against biofilm forming P. aeruginosa when NAC ≥ 0.5%
was used alone or in combination with Ciprodex® or cip-
rofloxacin, overcoming the resistance observed to solu-
tions containing ciprofloxacin alone.Figure 2 P. aeruginosa resistant strains: combined results for CiprodeThis study highlights the issue of in vitro antibiotic re-
sistance of P. aeruginosa to Ciprodex® and ciprofloxacin
otic solutions, with resistance levels as high as 13% and
40% for planktonic and sessile states respectively. Bac-
teria in biofilm (sessile) states exhibit exopolysaccharide-
cellular towers separated by open channels that deliver
nutrients and remove waste, a complex process requir-
ing cellular communication and modification of gene
regulation, but one that renders bacteria 10-1000 times
more resistant to antibiotic therapy versus genetically
identical planktonic forms [19]. However, NAC at con-
centrations ≥0.5% revealed universal susceptibility of all
P. aeruginosa strains from clinical isolates of patientsx and ciprofloxacin.
Figure 3 P. aeruginosa resistant strains to NAC alone. Figure abbreviation: NAC: N-acetylcysteine.
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findings are consistent with other in vitro studies show-
ing that NAC significantly inhibits the formation of bac-
terial biofilms when used alone. However, we failed to
duplicate the beneficial synergistic effect of NAC with
antimicrobial drugs that has previously been docu-
mented in the literature [16,20,21]. If the prior treatment
failure rates of 9-15% in patients with CSOM [5] are at-
tributed in whole or in part to biofilm formation, the
utilization of NAC alone or as an adjunct to ciprofloxa-
cin/dexamethasone (Ciprodex®) may culminate in im-
proved symptom resolution and patient benefit.
Paradoxically, 0.25% NAC alone, or as an adjunct to
Ciprodex® or ciprofloxacin yielded inferior susceptibility
in the sessile population when compared to either
Ciprodex® or ciprofloxacin alone. NAC 0.25% appeared
to maintain efficacy in the planktonic state, both alone
and in combined solutions with Ciprodex® and ciproflox-
acin. We hypothesize that this low concentration of
NAC (0.25%) may destabilize the outer surface of the
biofilms to allow some viable bacteria from the inner
layers to escape and grow. However, the true explanation
for this finding requires further study. The biofilm is a
dynamic biological complex, which may explain, in part,
issues of in-vitro reproducibility.
The identification of an agent such as NAC that eradi-
cates biofilms has potential for a significant clinical im-
pact in the management of patients with infectious
conditions in otolaryngology-head and neck surgery. A
high rate of Pseudomonas biofilms have been identified
on tympanostomy tubes in patients with persistent otor-
rhea despite treatment with ciprofloxacin otic drops [8].
Jang et.al, in a case series of 12 infected tympanostomy
tubes revealed ciprofloxacin resistant P.aeruginosa as the
sole organism with a high rate of tympanostomy tube
biofilm formation as shown by EM [8]. The topicalapplication of 20% NAC to the middle ear in patients
with tympanostomy tubes has been shown to increase
tube longevity, and to decrease the need for replacement
of tubes, and subsequent physician visits [22]. In a re-
cent case series of seven patients with CSOM and refrac-
tory otorrhea, use of Ciprodex® augmented with NAC
(0.5% or 2%) showed resolution of symptoms in 86% (6/
7) of patients within 4 weeks [17]. Compliance issues
were noted in the one subject with persistent otorrhea
refractory to treatment. No adverse effects were identi-
fied in treated patients with follow-up ranging from 14-
19 months. In particular, serial audiometry revealed no
changes in pure tone averages or speech discrimination
scores, thus supporting an absence of clinically signifi-
cant ototoxicity [17].
However, despite these promising findings regarding
the efficacy and safety of NAC, some prudence is war-
ranted with respect to the safety of intratympanic
administration of NAC. In our study, the low concentra-
tions of 0.5% and 1.25% NAC were utilized due to con-
cerns about NAC at higher concentrations [12,13].
Although NAC has been shown to have protective prop-
erties against ototoxicity related to Cisplatin [12,14], as
well as protection from noise induced hearing loss [15],
it has paradoxically also been implicated in causing in-
flammation and hearing loss.
In a recent study of 20% intratympanic NAC in a
guinea pig model, negative effects were seen including
increased ABR thresholds, inflammation of the external
auditory canal and middle ear mucosa, and diffuse oste-
itis with severe disruption of the organ of Corti on elec-
tron microscopy [13]. Similar inflammatory effects were
found on the external and middle ear of guinea pigs
treated with 4% intratympanic NAC [12]. In a guinea pig
cochlear implant model [23], although preservation of
residual hearing was found in the basal turn as well as a
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ated with cochlear implantation, a transient increase in
hearing thresholds and osseoneogenesis was also found
in animals treated with topical 4% NAC [23]. Topical
0.6% NAC after myringotomy in a guinea pig model
showed significant otorrhea in the NAC treated group
associated with reduced healing of the tympanic mem-
brane post-myringotomy; 40% had persistent TM perfo-
rations in the NAC treated group versus 100% closure of
perforations in the control group [24]. Two guinea pig
studies on intratympanic NAC for the prevention of Cis-
platin ototoxicity have demonstrated safety at NAC con-
centrations ≤4% [12,14]. NAC at a concentration of 4%
yields nuclear/cytoplasmic membrane and stereo-cilia
preservation on electron microscopy [12], and 2% NAC
leads to partial preservation of distortion product oto-
acoustic emissions [14]. While an inflammatory reaction
was seen in the 4% NAC group [12], none was observed
with 2% NAC (personal communication with Chang,
KW; unpublished data).
Human studies have shown a more promising side ef-
fect profile for intratympanic NAC compared to the ani-
mal studies. Yoo et al. reported no adverse events with
2% intratympanic NAC in patients receiving cisplatin
chemotherapy [25]. Riga et al, demonstrated clinical oto-
protective effects of 10% intratympanic NAC in a cohort
of patients treated with cisplatin based regimens based
on pure tone thresholds, with the only reported adverse
effect being pain post injection lasting less than five mi-
nutes (26). However, in the same study 20% intratympa-
nic NAC was trialed in five patients but discontinued
due to transient (<2 weeks) middle ear and tympanic
membrane inflammation [26]. The case series by Choe
et al. also demonstrates an absence of clinically signifi-
cant ototoxicity based on audiometric data in seven pa-
tients treated with intratympanic NAC ≤2% [17].
The evidence appears to trend toward increased safety
with reduced concentrations of topical NAC. Based on
current literature, intratympanic NAC <10% appears to
have an acceptable side effect profile based on clinical
human studies to date. However, long-term safety profile
data is currently unknown.
Conclusion
The combination of Ciprodex® with NAC has a shelf life
of at least two weeks given the documented preservation
of stability, sterility and clinical efficacy of the mixture. Re-
sistance of P. aeruginosa clinical isolates to both Ciprodex
and ciprofloxacin was demonstrated in this study, with
sessile bacteria having a higher incidence of resistance.
NAC at a concentration of ≥0.5% alone, or as an adjunct
to Ciprodex® or ciprofloxacin completely inhibited the
growth of both planktonic and sessile P. aeruginosa popu-
lations. NAC 0.25% revealed paradoxical results withincreased resistance in the sessile population and requires
further study. NAC shows promise as an agent in treat-
ment of bacteria implicated in CSOM in the laboratory
setting. Further study is warranted to delineate its efficacy
with topical administration in the clinical setting.
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